Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10379572 | 0.93 | NPC1 (0.74) | NPC1RAB9ASIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL12766913 | 0.92 | ALDH1A1 (0.64) | NPC1RAB9ASIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL1499415 | 0.88 | FYN (0.62) | NPC1RAB9ASIGMAR1MCHR1FYN | |
| SCHEMBL1499528 | 0.87 | NPC1 (0.62) | NPC1RAB9ASIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL10707297 | 0.84 | ALDH1A1 (0.73) | NPC1RAB9ASIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL22112729 | 0.84 | HDAC1 (0.64) | HPGDSMN1; SMN2KMT2ASIRT2NAMPT | |
| SCHEMBL10020214 | 0.83 | HPGD (0.79) | NPC1RAB9ASIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL15892524 | 0.83 | HPGD (0.59) | NPC1RAB9ASIGMAR1HPGDSMN1; SMN2 | |
| SCHEMBL1499478 | 0.82 | PTGS2 (0.59) | SIGMAR1HPGDMCHR1FYNALDH1A1 | |
| SCHEMBL29973570 | 0.82 | PTGS2 (0.59) | SIGMAR1HPGDMCHR1FYNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011509280-A | — | — | 2011-03-24 | — | — | JP | claimed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | claimed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | claimed |
| EP-3536691-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2022-10-05 | — | — | EP | disclosed |
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-2235000-B1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NAT RECH SCIENT (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| EP-3536691-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2019-09-11 | — | — | EP | disclosed |
| EP-3536691-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SPLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2019-09-11 | — | — | EP | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2235000-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009087238-A9 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009087238-A2 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654813-B2 | Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies | RBM17, RBM22, PRPF40A | NPC1 589/4885RAB9A 3640/4885SIGMAR1 3665/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | NPC1 2190/4885RAB9A 615/4885SIGMAR1 1284/4885 |
| US-20110053975-A1 | CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES | RBM17, SF3B5, SF3B1 | NPC1 922/4885RAB9A 4085/4885SIGMAR1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.